BioSpace News Archive

Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA ® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer To Stop for Futility and Patients to Discontinue...

Product revenue for the first nine months of 2020 increased 29 % year-over-year to $ 30.8 million R olling submission of the New Drug Application for CUTX-101 is expected to begin in the first quarter of 2021 and be completed by the end of the second quarter of 2021

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2020 and provided a business update. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, stated, “We are excited to have US WorldMeds in full control of our SYMJEPI product now that the transition from Sandoz has been completed. We expect to see the full impact of this transition going

Lantheus Holdings, Inc., the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB, and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, announced that management will present at two investor conferences in November.

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that IMV’s executive management team will participate at two upcoming virtual investor Conferences.

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported financial results for the third quarter ended September 30, 2020 and provided a business update

DENTSPLY SIRONA Inc., the Dental Solutions Company, announced that it will participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on November 11th.

The Cystic Fibrosis Registry Global Harmonization Group, including the CF Foundation, published in the Journal of Cystic Fibrosis updated data on the impact of COVID-19 on people with cystic fibrosis.

The NHS could improve patients’ access to new cancer treatments by paying different prices for drugs depending on the disease they are used to treat, concludes a group of experts from across academia and industry.

Dihydroergotamine mesylate (DHE) is Administered via Impel’s Proprietary Precision Olfactory Delivery (POD®) Technology, the First and Only Delivery System to Utilize the Vascular-Rich Upper Nasal Space as a Potential Treatment Pathway